Please assess the completion status of the following clinical trial:

Trial Title: CHF6563 in Babies With Neonatal Opioid Withdrawal Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Written informed consent obtained by parents/legal representative(according to local regulation) prior to or after birth.~2. Birth weight ≥ 3rd centile for gestational age (GA), according to the Centers for Disease Control and Prevention (CDC) growth chart~3. Gestational age ≥ 36 weeks~4. Exposure to opioids during the last month of fetal life~5. Signs of neonatal opioid withdrawal syndrome requiring treatment, and the sum of 3 consecutive FNAST scores is ≥ 24 or a single score ≥ 12~Exclusion Criteria:~1. Familial history of prolonged QTc syndrome~2. Major congenital malformations or evidence of congenital infection~3. Signs of fetal alcohol spectrum disorders~4. Maternal alcohol abuse, defined as average of 3 or more drinks per week in the last 30 days~5. Medical illness at the time of randomization, including but not exclusively:~   1. Neonatal hypoglycemia requiring intravenous glucose therapy~  2. Neonatal respiratory illness requiring non-invasive or invasive respiratory support~  3. Neonatal encephalopathy (including hypoxic ischemic encephalopathy or seizures~  4. Severe hyperbilirubinemia-bilirubin at or above the exchange transfusion threshold as defined by the American Academy of Pediatrics (AAP)~  5. Severe elevation of serum aminotransferases (more than twice the upper limit of the age appropriate aminotransferases reference range of the investigational site).~  6. Proven or suspected early onset neonatal infection which will require more than 48 hours treatment with antibiotics~6. Unable to tolerate an oral or sublingual medication~7. Need for medications forbidden in this study protocol~8. Any condition that, in the opinion of the Investigator, would place the neonate at undue risk~9. Participation in another clinical trial of any medicinal product, placebo, experimental medical device or biological substance conducted under the provisions of a protocol on the same therapeutic target. The participation in studies involving diagnostic devices or treatments for conditions other than NOWS and Neonatal abstinence syndrome (NAS) may be permitted following an agreement with the Sponsor. Non-interventional observational studies are allowed

- Gender: ALL
- Minimum Age: None
- Maximum Age: 7 Days
- Healthy Volunteers: f

Study Arms:
- CHF6563 (Type: EXPERIMENTAL): Sublingual dose of CHF6563 and the corresponding oral dose of morphine matched placebo
- Morphine (Type: ACTIVE_COMPARATOR): Oral dose of morphine and the corresponding sublingual dose of CHF6563 matched placebo.

Based on this trial design, predict the completion outcome and termination type (if applicable).